心泰醫療(02291.HK)發售價定為每股29.15港元 預計11月8日掛牌上市
格隆匯11月7日丨心泰醫療(02291.HK)發佈公吿,公司全球發售2245.5萬股股份,其中香港發售股份224.6萬股,國際發售股份2020.9萬股,另有15%超額配股權;發售價已釐定為每股發售股份29.15港元,每手買賣單位1000股;中金公司為獨家保薦人;預期股份將於2022年11月8日於聯交所主板掛牌上市。
香港公開發售項下初步提呈發售的香港發售股份已獲略微超額認購。公司已接獲合共668份有效申請,相當於香港公開發售項下初步可供認購的股份總數的約2.11倍。國際發售項下初步提呈發售的發售股份已獲略微超額認購,約為國際發售項下初步可供認購發售股份總數的1.38倍。按發售價每股發售股份29.15港元計算,並根據基石投資協議,基石投資者認購的發售股份數目已經確定。Harvest、臨港及Jointown International已分別認購269.2萬股、263.8萬股及134.6萬股,共計667.6萬股發售股份。
按發售價每股發售股份29.15港元計算,並假設超額配售權未獲行使,公司將收取的全球發售所得款項淨額估計約為5.673億港元。其中所得款項淨額的約50.7%將用於為公司未來五年內的研發活動提供資金;約24.3%將用於公司未來五年內的銷售及營銷活動;約5.0%將用於在未來五年內提升公司的產能及加強制造能力;約10.0%將用於為未來五年內潛在的戰略投資及收購提供資金;及所得款項淨額的約10.0%將用於公司營運資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.